Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR<i>Stenotrophomonas maltophilia</i>

Abstract

Despite lack of activity in standard MIC testing, azithromycin synergizes with cationic peptide antibiotics to kill SM in medium mimicking tissue fluid conditions. Azithromycin, alone or in combination with colistin, merits further exploration in therapy of drug-resistant SM infections.